Skip to content

Vincristine Liposomal

    Brands

    DEA Class; Rx

    Common Brand Names; Marqibo

    • Antineoplastics, Vinca Alkaloid

    Liposome-encapsulated formulation of vincristine sulfate, a vinca alkaloid agent
    Used for the treatment of adult patients with relapsed Philadelphia chromosome-negative ALL
    Neurologic toxicity (e.g., peripheral neuropathy and paralytic ileus) and myelosuppression have been reported

    Indicated for treating Philadelphia chromosome-negative acute lymphoblastic leukemia in adults with second or greater relapse or whose disease has progressed following 2 or more antileukemia therapies
    For the treatment of Philadelphia chromosome-negative acute lymphocytic leukemia (ALL) in second or greater relapse or that has progressed after 2 or more anti-leukemia therapies.

    Hypersensitivity

    Demyelinating conditions including Charcot-Marie-Tooth syndrome

    Intrathecal administration

    • Blood and lymphatic system disorders (56.6%)
    • Infections (39.8%)
    • General disorders and administration site condition (37.3%)
    • Neuropathy (32.5%)
    • Febrile neutropenia (31.3%)
    • Respiratory thoracic and mediastinal disorders (20.5%)
    • Investigations (24.1%)
    • Gastrointestinal disorders (25.3%)
    • Neutropenia (18.1%)
    • Peripheral sensory and motor neuropathy (16.7%)
    • Anemia (16.9%)
    • Thrombocytopenia (16.9%)
    • Pyrexia (14.5%)
    • Fatigue (12%)
    • Psychiatric disorders (10.8%)
    • Cardiac disorders (10.8%)

    For IV use only; other routes may result in fatalities

    Death has occurred with intrathecal administration

    Do not confuse liposomal injection with vincristine injection due to different dosage recommendations; verify drug name and dose prior to administration

    Based on its mechanism of action and findings from animal studies, there are insufficient data on use in pregnant women to evaluate for a drug-associated risk; drug can cause fetal harm when administered to pregnant women

    If drug is used during pregnancy, or if patient becomes pregnant while taking drug, patient should be apprised of potential hazard to fetus

    There are no data on presence of drug or metabolites in human milk, effects on breastfed child, or on milk production

    Adults

    2.25 mg/m2 IV every 7 days.

    Geriatric

    2.25 mg/m2 IV every 7 days.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Vincristine sulfate liposome

    intravenous injection

    • 5mg/31mL (0.16mg/mL) final concentration following constitution
    • Supplied as a kit that also contains sphingomyelin/cholesterol liposome injection (73.5mg/29.5mg/vial)